Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)

Ronan T. Swords, Peter L. Greenberg, Andrew H. Wei, Simon Durrant, Anjali S. Advani, Mark S. Hertzberg, Ian D. Lewis, Gabriel Rivera, Dita Gratzinger, Alice C. Fan, Dean W. Felsher, Jorge E. Cortes, Justin M. Watts, Geoff T. Yarranton, Jackie M. Walling, Jeffrey E. Lancet

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Fingerprint

Dive into the research topics of 'Corrigendum to “KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study” [Leuk. Res. 50 (Nov) (2016) 123–131. PubMed PMID: 27736729](S0145212616301989)(10.1016/j.leukres.2016.09.012)'. Together they form a unique fingerprint.

Medicine & Life Sciences